Primary outcome
n=2/8
At 12 months after randomisation, nine participants (50%; IVIG n=5/10 (50%); placebo n=4/8 (50%)) made a good recovery, defined as a GOS-E Peds score of ≤2. Five participants (28%; IVIG n=3/10 (30%), placebo n=2/8 (25%)) made a poor recovery, defined as a GOS-E Peds score of >2. Four participants (22%; IVIG n=2/10 (20%), placebo n=2/8 (25%)) did not undergo a GOS-E Peds assessment at this timepoint. GOS-E Peds scores at 12 months after randomisationGOSE-Peds, Paediatric Glasgow Outcome Score Extended; IVIG, intravenous immunoglobulin.